the role of the multidisciplinary team in providing adequate diagnosis & treatment for bpdcn
Published 1 year ago • 44 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
0:35
mds: the role of the multidisciplinary team
-
2:38
the role of the multidisciplinary team in cardiac amyloidosis
-
1:16
the importance of multidisciplinary collaboration in the classification of lymphomas
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
3:57
validation of the ipss-m risk stratification system in mds
-
2:41
a phase i/ii study of afm13 in combination with cord blood-derived nk cells in patients with r/r hl
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
2:26
an insight into the aims of the eurasian hematology-oncology group
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
7:14
phase iii medalist trial of luspatercept for mds
-
9:41
subcutaneous epcoritamab in r/r b-cell non-hodgkin lymphoma
-
4:18
phase i trial investigating cd8-depleted hla-mismatched unrelated dli in patients with mds and aml
-
4:12
novel therapies in low-risk mds
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:20
regulation of tetraspanin cd63 in cml progression: single-cell analysis of asymmetric hsc division
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
2:52
updated analysis of phase iii trial of idelalisib combined with bendamustine and rituximab in cll
-
1:41
oral time-limited duvelisib/venetoclax in r/r cll
-
2:10
updated overall survival data on eltanexor for hma-refractory mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
2:22
epcore cll-1: phase i trial of epcoritamab in r/r cll
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space